ClinicalTrials.gg

Narcolepsy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 158 studies for Narcolepsy across more than 10 countries. 38 are recruiting or about to start. 118 of them are mainly about Narcolepsy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Cataplexy too: 160 studies, 38 open.

Status

Completed
100
Recruiting
30
Status unknown
7
Not yet recruiting
6
Terminated
6
Withdrawn
2

Phase

Phase 3
36
Phase 2
30
Phase 1
20
Phase 4
4
Early Phase 1
1

Where

United States
85
France
49
Canada
24
Spain
23
Italy
22
Netherlands
16

Who develops what

Add Narcolepsy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 9 companies, 10 with this as their studies’ main aim; 6 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Eli Lilly, Jazz Pharmaceuticals and Takeda here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
oveporexton☆ Track2 live phase-3 studies: NCT07363720, NCT05816382Takeda
alixorexton☆ Track2 live phase-3 studies: NCT06767683, NCT07455383Alkermes, Inc.
cleminorexton☆ Track1 live phase-3 study: NCT07598708Eli Lilly and Company
HBS-301☆ Track1 live phase-3 study: NCT07675135Harmony Biosciences Holdings, Inc.
JZP258Phase 4 trial recorded☆ Track1 live phase-3 study: NCT07625280Jazz Pharmaceuticals

The 5 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.TAK-360 · Takeda · Phase 2 main aimNCT06952699 A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) — primary endpoint: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) · 88 enrolled
  • 17 Dec 2026 est.oveporexton · Takeda · Phase 3 main aimNCT07363720 A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy — primary endpoint: Time to Loss of Response in the Epworth Sleepiness Scale (ESS) Score During the Up to 4-Week RW Period · 98 enrolled
  • 14 Feb 2027 est.ledasorexton · Eisai Co., Ltd. · Phase 2 main aimNCT07493265 A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy — primary endpoint: Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2 · 64 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Narcolepsy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Stimulants 1 open

Coming up

19studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger. 12 (40%) take children under 18. 2 (7%) are for women only and 0 (0%) for men only; 6 (20%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
1010 (33%)8 (27%)
1829 (97%)27 (90%)
3029 (97%)27 (90%)
4029 (97%)27 (90%)
5029 (97%)27 (90%)
6524 (80%)22 (73%)
7516 (53%)14 (47%)
8514 (47%)12 (40%)

Across all 158 studies, recruiting or not: 57% stop at 75 or younger and 39% at 65; 34% take children; 3% are for women only and 1% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Narcolepsy studies take

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo3–11 · 13 studies——
Phase 214 mo11–44 · 15 studies——
Phase 330 mo21–40 · 14 studies——
Interventional, no phase23 mo15–42 · 21 studies——
Observational61 mo14–73 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 158. Browse all 158 → or search them.